` 0Y5F (Endo International PLC) vs S&P 500 Comparison - Alpha Spread

0Y5F
vs
S&P 500

Over the past 12 months, 0Y5F has underperformed S&P 500, delivering a return of 7% compared to the S&P 500's 12% growth.

Stocks Performance
0Y5F vs S&P 500

Loading

Performance Gap
0Y5F vs S&P 500

Loading
0Y5F
S&P 500
Difference

Performance By Year
0Y5F vs S&P 500

Loading
0Y5F
S&P 500
Add Stock

Competitors Performance
Endo International PLC vs Peers

S&P 500
0Y5F
LLY
JNJ
NOVO B
ROG
Add Stock

Endo International PLC
Glance View

Market Cap
163.5B USD
Industry
Pharmaceuticals

Endo International PLC is a specialty pharmaceutical company that operates at the intersection of innovation and necessity within the healthcare industry. Its primary business involves developing, manufacturing, and marketing both branded and generic pharmaceutical products. Endo thrives on a diversified portfolio that spans numerous therapeutic areas, including pain management, urology, orthopedics, and endocrinology. The company strategically positions itself by addressing unmet medical needs, often targeting niche markets where the competition is minimal, thus allowing for premium pricing and robust profit margins. Endo's revenue streams are driven by a blend of proprietary and generic drugs, with a significant portion coming from its well-known brands such as PERCOCET® and SUPPRELIN® LA. Its generics division supplements this by producing cost-effective versions of popular drugs, supporting market accessibility and appealing to cost-sensitive consumers and healthcare providers. By leveraging its research and development capabilities, Endo continues to enhance its product portfolio and explore new market opportunities. The company's growth is rooted in its ability to adapt to the ever-changing regulatory landscape, optimize its operations for efficiency, and forge strategic partnerships that enhance its market reach.

0Y5F Intrinsic Value
Not Available
E
Back to Top